Publications by Vilde Drageset Haakensen

42 publications found

Publications 2024

1. Farooqi SJ, Zhao Z, Öjlert ÅK, Thunold S, Juul HV, Bjaanæs MM, Horndalsveen H, Nymoen HMG, Helland Å, Haakensen VD (2024)
   Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma
   Front Immunol, 15, 1480183
   DOI 10.3389/fimmu.2024.1480183, PubMed 39687621
2. Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N (2024)
   Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
   ESMO Open, 9 (6), 103464
   DOI 10.1016/j.esmoop.2024.103464, PubMed 38833971
3. Gullhaug A, Haakensen VD, De Ruysscher D, Simone CB, Hotca-Cho AE, Chhabra AM, Hellebust TP, Paulsen EE, Dimopoulos MP, Johansen S (2024)
   Lung cancer reirradiation: Exploring modifications to utilization, treatment modalities and factors associated with outcomes
   J Med Imaging Radiat Sci, 55 (2), 221-231
   DOI 10.1016/j.jmir.2024.02.004, PubMed 38429174
4. Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å (2024)
   UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
   Eur J Cancer, 202, 113973
   DOI 10.1016/j.ejca.2024.113973, PubMed 38447379
5. Nymoen HM, Alver TN, Horndalsveen H, Eide HA, Bjaanæs MM, Brustugun OT, Grønberg BH, Haakensen VD, Helland Å (2024)
   Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial
   Front Oncol, 14, 1412716
   DOI 10.3389/fonc.2024.1412716, PubMed 39148905
6. Thunold S, Hernes E, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, Szejniuk WM, Nielsen SS, Cedres S, Perdigo MS, Sørensen JB, Meltzer C, Mikalsen LTG, Helland Å, Malinen E, Haakensen VD (2024)
   Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine
   Eur J Nucl Med Mol Imaging (in press)
   DOI 10.1007/s00259-024-06853-0, PubMed 39133306

Publications 2023

1. Langberg CW, Horndalsveen H, Helland Å, Haakensen VD (2023)
   Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
   Front Oncol, 13, 1217424
   DOI 10.3389/fonc.2023.1217424, PubMed 37476372

Publications 2022

1. Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B (2022)
   Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
   J Thorac Oncol, 18 (2), 181-193
   DOI 10.1016/j.jtho.2022.10.003, PubMed 36307040
2. Gulati G, Tjessem KH, Horndalsveen H, Halvorsen S, Haakensen VD (2022)
   [Checkpoint inhibitor-induced myocarditis]
   Tidsskr Nor Laegeforen, 142 (18)
   DOI 10.4045/tidsskr.21.0817, PubMed 36511752
3. Horndalsveen H, Alver TN, Dalsgaard AM, Rogg LV, Helbekkmo N, Grønberg BH, Halvorsen TO, Ramberg C, Haakensen VD, Öjlert ÅK, Bjaanaes MM, Helland Å (2022)
   Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial
   Mol Oncol, 17 (3), 487-498
   DOI 10.1002/1878-0261.13330, PubMed 36330681
4. Khadse A, Haakensen VD, Silwal-Pandit L, Hamfjord J, Micke P, Botling J, Brustugun OT, Lingjærde OC, Helland Å, Kure EH (2022)
   Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
   Front Oncol, 12, 873532
   DOI 10.3389/fonc.2022.873532, PubMed 35574381

Publications 2021

1. Bjaanæs MM, Sande EPS, Loe Ø, Ramberg C, Næss TM, Ottestad A, Rogg LV, Svestad JG, Haakensen VD (2021)
   Improved adaptive radiotherapy to adjust for anatomical alterations during curative treatment for locally advanced lung cancer
   Phys Imaging Radiat Oncol, 18, 51-54
   DOI 10.1016/j.phro.2021.04.003, PubMed 34258408
2. Farooqi SJ, Bjaanæs MM, Helland Å, Haakensen VD (2021)
   [Immunotherapy for malignant pleural mesothelioma]
   Tidsskr Nor Laegeforen, 141
   DOI 10.4045/tidsskr.21.0503, PubMed 34505475
3. Farooqi SJ, Helland A, Haakensen VD, Bjaanaes MM (2021)
   Immunotherapy in malignant pleural mesothelioma
   Tidsskr. Nor. Laegeforen., 141 (12), 1167-1169
4. Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å (2021)
   NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
   J Transl Med, 19 (1), 232
   DOI 10.1186/s12967-021-02905-3, PubMed 34059094
5. Terkelsen T, Pernemalm M, Gromov P, Børresen-Dale AL, Krogh A, Haakensen VD, Lethiö J, Papaleo E, Gromova I (2021)
   High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers
   Mol Oncol, 15 (2), 429-461
   DOI 10.1002/1878-0261.12850, PubMed 33176066

Publications 2020

1. Haakensen VD, Khadse A, Sandhu V, Halvorsen AR, Solberg SK, Jørgensen LH, Brustugun OT, Kure EH, Helland Å (2020)
   Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
   Int J Cancer, 147 (10), 2957-2966
   DOI 10.1002/ijc.33121, PubMed 32468587
2. Terkelsen T, Russo F, Gromov P, Haakensen VD, Brunak S, Gromova I, Krogh A, Papaleo E (2020)
   Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration
   Breast Cancer Res, 22 (1), 73
   DOI 10.1186/s13058-020-01295-6, PubMed 32605588

Publications 2019

1. Bergholtz H, Lien TG, Ursin G, Holmen MM, Helland Å, Sørlie T, Haakensen VD (2019)
   A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue
   J Mammary Gland Biol Neoplasia, 24 (2), 163-175
   DOI 10.1007/s10911-018-09423-x, PubMed 30613869
2. Nygård S, Lingjærde OC, Caldas C, Hovig E, Børresen-Dale AL, Helland Å, Haakensen VD (2019)
   PathTracer: High-sensitivity detection of differential pathway activity in tumours
   Sci Rep, 9 (1), 16332
   DOI 10.1038/s41598-019-52529-3, PubMed 31704995

Publications 2018

1. Jabeen S, Espinoza JA, Torland LA, Zucknick M, Kumar S, Haakensen VD, Lüders T, Engebraaten O, Børresen-Dale AL, Kyte JA, Gromov P, Naume B, Kristensen V, Gromova I, Tekpli X (2018)
   Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
   Oncoimmunology, 8 (2), e1537691
   DOI 10.1080/2162402X.2018.1537691, PubMed 30713794
2. Terkelsen T, Haakensen VD, Saldova R, Gromov P, Hansen MK, Stöckmann H, Lingjaerde OC, Børresen-Dale AL, Papaleo E, Helland Å, Rudd PM, Gromova I (2018)
   N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome
   Mol Oncol, 12 (6), 972-990
   DOI 10.1002/1878-0261.12312, PubMed 29698574

Publications 2017

1. Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, Kristensen VN, Troyanskaya OG (2017)
   Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
   Oncotarget, 8 (34), 57121-57133
   DOI 10.18632/oncotarget.19078, PubMed 28915659
2. Saldova R, Haakensen VD, Rødland E, Walsh I, Stöckmann H, Engebraaten O, Børresen-Dale AL, Rudd PM (2017)
   Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up
   Mol Oncol, 11 (10), 1361-1379
   DOI 10.1002/1878-0261.12105, PubMed 28657165

Publications 2016

1. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E, Barrowdale D, Sinnott-Armstrong NA, Sallari RC, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lee JS, Hills M, Jarosz M, Drury S, Canisius S, Bolla MK, Dennis J et al. (2016)
   Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170
   Nat Genet, 48 (4), 374-86
   DOI 10.1038/ng.3521, PubMed 26928228
2. Eide HA, Halvorsen AR, Sandhu V, Fåne A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland Å (2016)
   Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
   Clin Transl Immunology, 5 (11), e109
   DOI 10.1038/cti.2016.65, PubMed 27990285
3. Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Timmermans Wielenga V, Møller Talman ML, Brunner N, Børresen-Dale AL, Gromov P, Helland Å, Kristensen VN, Gromova I (2016)
   Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics
   Oncoimmunology, 5 (12), e1248015
   DOI 10.1080/2162402X.2016.1248015, PubMed 28123884
4. Halvorsen AR, Helland Å, Gromov P, Wielenga VT, Talman MM, Brunner N, Sandhu V, Børresen-Dale AL, Gromova I, Haakensen VD (2016)
   Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer
   Mol Oncol, 11 (2), 220-234
   DOI 10.1002/1878-0261.12025, PubMed 28145100
5. Haakensen VD, Nygaard V, Greger L, Aure MR, Fromm B, Bukholm IR, Lüders T, Chin SF, Git A, Caldas C, Kristensen VN, Brazma A, Børresen-Dale AL, Hovig E, Helland Å (2016)
   Subtype-specific micro-RNA expression signatures in breast cancer progression
   Int J Cancer, 139 (5), 1117-28
   DOI 10.1002/ijc.30142, PubMed 27082076

Publications 2015

1. Darabi H, McCue K, Beesley J, Michailidou K, Nord S, Kar S, Humphreys K, Thompson D, Ghoussaini M, Bolla MK, Dennis J, Wang Q, Canisius S, Scott CG, Apicella C, Hopper JL, Southey MC, Stone J, Broeks A, Schmidt MK, Scott RJ, Lophatananon A, Muir K, Beckmann MW, Ekici AB et al. (2015)
   Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
   Am J Hum Genet, 97 (1), 22-34
   DOI 10.1016/j.ajhg.2015.05.002, PubMed 26073781
2. Haakensen VD, Steinfeld I, Saldova R, Shehni AA, Kifer I, Naume B, Rudd PM, Børresen-Dale AL, Yakhini Z (2015)
   Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome
   Mol Oncol, 10 (1), 59-72
   DOI 10.1016/j.molonc.2015.08.002, PubMed 26321095
3. Potapenko IO, Lüders T, Russnes HG, Helland Å, Sørlie T, Kristensen VN, Nord S, Lingjærde OC, Børresen-Dale AL, Haakensen VD (2015)
   Glycan-related gene expression signatures in breast cancer subtypes; relation to survival
   Mol Oncol, 9 (4), 861-76
   DOI 10.1016/j.molonc.2014.12.013, PubMed 25655580

Publications 2014

1. Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis ML, Haakensen VD, Wärnberg F, Naume B, Helland A, Børresen-Dale AL, Tost J, Christensen BC, Kristensen VN (2014)
   Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis
   Genome Biol, 15 (8), 435
   DOI 10.1186/PREACCEPT-2333349012841587, PubMed 25146004
2. Saldova R, Asadi Shehni A, Haakensen VD, Steinfeld I, Hilliard M, Kifer I, Helland A, Yakhini Z, Børresen-Dale AL, Rudd PM (2014)
   Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC
   J Proteome Res, 13 (5), 2314-27
   DOI 10.1021/pr401092y, PubMed 24669823

Publications 2013

1. Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, Kaspi A, Hu R, Robens J, Nikolskaya T, Haakensen VD, Schnitt SJ, Argani P, Ethington G, Panos L, Grant M et al. (2013)
   Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics
   Cell Stem Cell, 13 (1), 117-30
   DOI 10.1016/j.stem.2013.05.004, PubMed 23770079

Publications 2012

1. Riis ML, Lüders T, Markert EK, Haakensen VD, Nesbakken AJ, Kristensen VN, Bukholm IR (2012)
   Molecular profiles of pre- and postoperative breast cancer tumours reveal differentially expressed genes
   ISRN Oncol, 2012, 450267
   DOI 10.5402/2012/450267, PubMed 23227362

Publications 2011

1. Haakensen VD, Bjøro T, Lüders T, Riis M, Bukholm IK, Kristensen VN, Troester MA, Homen MM, Ursin G, Børresen-Dale AL, Helland Å (2011)
   Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas
   BMC Cancer, 11, 332
   DOI 10.1186/1471-2407-11-332, PubMed 21812955
2. Haakensen VD, Lingjaerde OC, Lüders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, Børresen-Dale AL, Helland A (2011)
   Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features
   BMC Med Genomics, 4, 77
   DOI 10.1186/1755-8794-4-77, PubMed 22044755
3. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale AL (2011)
   Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
   Proc Natl Acad Sci U S A, 109 (8), 2802-7
   DOI 10.1073/pnas.1108781108, PubMed 21908711

Publications 2010

1. Haakensen VD, Biong M, Lingjærde OC, Holmen MM, Frantzen JO, Chen Y, Navjord D, Romundstad L, Lüders T, Bukholm IK, Solvang HK, Kristensen VN, Ursin G, Børresen-Dale AL, Helland A (2010)
   Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density
   Breast Cancer Res, 12 (4), R65
   DOI 10.1186/bcr2632, PubMed 20799965

Publications 2009

1. Potapenko IO, Haakensen VD, Lüders T, Helland A, Bukholm I, Sørlie T, Kristensen VN, Lingjaerde OC, Børresen-Dale AL (2009)
   Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression
   Mol Oncol, 4 (2), 98-118
   DOI 10.1016/j.molonc.2009.12.001, PubMed 20060370

Publications 2006

1. Drageset V, Nesland JM, Erikstein B, Skovlund E, Sommer H, Anker G, Wist E, Lundgren S, Bergh J, Kvalheim G (2006)
   Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
   Int J Cancer, 118 (11), 2877-81
   DOI 10.1002/ijc.21709, PubMed 16381016